Haleon Appoints Richard Manso as US Chief Marketing Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy HLN?
Haleon announced the appointment of Richard Manso as US Chief Marketing Officer. In this role, Manso will partner closely with CEO, US & President, North America Nathalie Gerschtein and the US leadership team to accelerate Haleon's evolution into a more agile, consumer-centric organization. Manso will lead Haleon's integrated US marketing organization, advancing how the company connects with consumers in the moments where health decisions actually happen. He will work across categories and global teams to integrate data, technology and human insight, strengthening Haleon's ability to deliver more personalized, transparent and relevant health experiences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HLN
Wall Street analysts forecast HLN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 9.300
Low
13.44
Averages
13.44
High
13.44
Current: 9.300
Low
13.44
Averages
13.44
High
13.44
About HLN
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Haleon Appoints New US Chief Marketing Officer
- Executive Appointment: Haleon has announced the appointment of Richard Manso as US Chief Marketing Officer effective April 27, 2026, tasked with driving the company's evolution into a more agile, consumer-centric organization, which is expected to enhance its competitive position in the consumer health sector.
- Market Strategy: Manso will lead Haleon's integrated US marketing team, focusing on enhancing consumer experiences in health decision-making through the integration of data, technology, and human insights, thereby strengthening brand trust and customer loyalty.
- Industry Context: Manso's appointment comes at a significant transformation period in consumer health, where rising consumer expectations for personalized, transparent, and on-demand experiences make marketing increasingly critical in shaping brand identity and customer relationships.
- Future Outlook: Manso's extensive experience at Google will bring a fresh perspective to Haleon, aiding the company in building closer consumer connections in health management and driving future growth, particularly in priority areas such as Medicare Advantage OTC and Women's and Pediatric Health.
See More
NASDAQ 100 Pre-Market Update Highlights Active Stocks
- Pre-Market Indicator Rise: The NASDAQ 100 Pre-Market Indicator increased by 108.49 points to 24,642.07, indicating a positive market sentiment that could set the tone for today's trading.
- Active Stock Performance: Haleon plc (HLN) is trading at $10.06, which is 75.07% of its target price of $13.4, reflecting cautious market sentiment regarding its future performance.
- Nokia Price Recovery: Nokia Corporation (NOK) rose by $0.15 to $8.29, currently exceeding its target price of $7.73 by 107.24%, indicating optimistic market expectations for its prospects.
- Circle Internet Group's Positive Outlook: Circle Internet Group, Inc. (CRCL) increased by $3.89 to $118.07, currently surpassing its target price of $98 by 120.48%, with upward revisions in its EPS forecast for fiscal Q3 2026, suggesting improved earnings expectations.
See More
parodontax Launches New Gum Care Toothpaste and Mouthwash
- Product Innovation: parodontax has launched the new Gum Strengthen & Protect toothpaste and mouthwash, featuring hyaluronic acid to enhance gum protection with continued twice-daily use, helping consumers maintain oral health.
- Ingredient Benefits: The new products leverage hyaluronic acid for improved foaming and freshness, with the toothpaste strengthening the seal between gums and teeth, while the mouthwash effectively kills plaque bacteria along the gumline to support hydration.
- Market Demand: As consumers increasingly prioritize preventative health habits, gum health is becoming a crucial aspect of oral care, with parodontax's research indicating links between gum issues and conditions like heart disease and diabetes.
- Sales Channels: The new products are now available at major retailers including Amazon, Walmart, CVS, and Target, aiming to enhance consumer frequency of use through convenient purchasing options.
See More
Haleon Invests £65M to Expand Oral Health Manufacturing in China
- Market Expansion Plan: Haleon aims to extend its oral health brand parodontax to 30 cities in China by the end of 2027, reaching over 250 million consumers, thereby driving sales growth to meet the rising middle-class demand for trusted international brands.
- New Factory Investment: The company is investing £65 million in a new oral health manufacturing plant in Shanghai, enhancing its local production capabilities to respond more swiftly to consumer preferences and accelerate innovation, supporting its goal of reaching one billion consumers by 2030.
- Product Localization: To resonate with Chinese consumers, Haleon's global R&D team collaborated with local scientists to adapt the flavor and packaging of parodontax, ensuring a blend of clinical efficacy and consumer preferences, thus enhancing market competitiveness.
- Market Opportunity: With China's gum health market valued at approximately £860 million and over 70% of adults experiencing gum issues, Haleon's investment positions it favorably in this rapidly growing market, catering to the demand for clinically proven products.
See More
Daily Multivitamin May Slow Biological Aging, Study Finds
- Study Background: An analysis of the COSMOS randomized trial indicates that Centrum Silver may help slow biological aging markers, led by researchers from Mass General Brigham and Augusta University, involving nearly 1,000 older participants over two years.
- Biological Aging Slowed: Participants taking the multivitamin showed slowing in all five epigenetic clocks compared to the placebo group, with significant reductions in two clocks predictive of mortality, equating to about four months less biological aging over two years.
- Accelerated Aging Benefits: The study found that participants with accelerated biological aging at baseline experienced greater benefits from the multivitamin, suggesting that this intervention may be particularly effective for individuals with higher biological age, potentially providing crucial insights for long-term health outcomes.
- Strategic Implications: This research offers new evidence for the potential role of multivitamins in healthy aging, highlighting Centrum Silver as a safe, low-cost intervention that may play a significant role in promoting health among older adults.
See More
Haleon plc Reports Profit Growth for Fiscal 2025 Despite Revenue Decline
- Significant Profit Growth: Haleon plc reported a 12.7% increase in fiscal 2025 profit before tax, reaching £2.15 billion, up from £1.91 billion last year, demonstrating strong profitability despite a revenue decline.
- Earnings Per Share Increase: The company's earnings per share rose by 17.8%, from 15.7 pence to 18.5 pence, reflecting successful cost control and operational efficiency, which enhances shareholder return expectations.
- Share Buyback Plan: Haleon announced a £500 million allocation for share buybacks in 2026, a move aimed not only at boosting earnings per share but also reflecting confidence in future cash flows, thereby enhancing market recognition of its long-term value.
- Future Growth Outlook: The company expects organic revenue growth of 3% to 5% for fiscal 2026, alongside high single-digit adjusted operating profit growth, indicating Haleon's strategic commitment to enhancing profitability and market competitiveness.
See More
Haleon Appoints New US Chief Marketing Officer
- Executive Appointment: Haleon has announced the appointment of Richard Manso as US Chief Marketing Officer effective April 27, 2026, tasked with driving the company's evolution into a more agile, consumer-centric organization, which is expected to enhance its competitive position in the consumer health sector.
- Market Strategy: Manso will lead Haleon's integrated US marketing team, focusing on enhancing consumer experiences in health decision-making through the integration of data, technology, and human insights, thereby strengthening brand trust and customer loyalty.
- Industry Context: Manso's appointment comes at a significant transformation period in consumer health, where rising consumer expectations for personalized, transparent, and on-demand experiences make marketing increasingly critical in shaping brand identity and customer relationships.
- Future Outlook: Manso's extensive experience at Google will bring a fresh perspective to Haleon, aiding the company in building closer consumer connections in health management and driving future growth, particularly in priority areas such as Medicare Advantage OTC and Women's and Pediatric Health.
See More
NASDAQ 100 Pre-Market Update Highlights Active Stocks
- Pre-Market Indicator Rise: The NASDAQ 100 Pre-Market Indicator increased by 108.49 points to 24,642.07, indicating a positive market sentiment that could set the tone for today's trading.
- Active Stock Performance: Haleon plc (HLN) is trading at $10.06, which is 75.07% of its target price of $13.4, reflecting cautious market sentiment regarding its future performance.
- Nokia Price Recovery: Nokia Corporation (NOK) rose by $0.15 to $8.29, currently exceeding its target price of $7.73 by 107.24%, indicating optimistic market expectations for its prospects.
- Circle Internet Group's Positive Outlook: Circle Internet Group, Inc. (CRCL) increased by $3.89 to $118.07, currently surpassing its target price of $98 by 120.48%, with upward revisions in its EPS forecast for fiscal Q3 2026, suggesting improved earnings expectations.
See More
parodontax Launches New Gum Care Toothpaste and Mouthwash
- Product Innovation: parodontax has launched the new Gum Strengthen & Protect toothpaste and mouthwash, featuring hyaluronic acid to enhance gum protection with continued twice-daily use, helping consumers maintain oral health.
- Ingredient Benefits: The new products leverage hyaluronic acid for improved foaming and freshness, with the toothpaste strengthening the seal between gums and teeth, while the mouthwash effectively kills plaque bacteria along the gumline to support hydration.
- Market Demand: As consumers increasingly prioritize preventative health habits, gum health is becoming a crucial aspect of oral care, with parodontax's research indicating links between gum issues and conditions like heart disease and diabetes.
- Sales Channels: The new products are now available at major retailers including Amazon, Walmart, CVS, and Target, aiming to enhance consumer frequency of use through convenient purchasing options.
See More
Haleon Invests £65M to Expand Oral Health Manufacturing in China
- Market Expansion Plan: Haleon aims to extend its oral health brand parodontax to 30 cities in China by the end of 2027, reaching over 250 million consumers, thereby driving sales growth to meet the rising middle-class demand for trusted international brands.
- New Factory Investment: The company is investing £65 million in a new oral health manufacturing plant in Shanghai, enhancing its local production capabilities to respond more swiftly to consumer preferences and accelerate innovation, supporting its goal of reaching one billion consumers by 2030.
- Product Localization: To resonate with Chinese consumers, Haleon's global R&D team collaborated with local scientists to adapt the flavor and packaging of parodontax, ensuring a blend of clinical efficacy and consumer preferences, thus enhancing market competitiveness.
- Market Opportunity: With China's gum health market valued at approximately £860 million and over 70% of adults experiencing gum issues, Haleon's investment positions it favorably in this rapidly growing market, catering to the demand for clinically proven products.
See More
Daily Multivitamin May Slow Biological Aging, Study Finds
- Study Background: An analysis of the COSMOS randomized trial indicates that Centrum Silver may help slow biological aging markers, led by researchers from Mass General Brigham and Augusta University, involving nearly 1,000 older participants over two years.
- Biological Aging Slowed: Participants taking the multivitamin showed slowing in all five epigenetic clocks compared to the placebo group, with significant reductions in two clocks predictive of mortality, equating to about four months less biological aging over two years.
- Accelerated Aging Benefits: The study found that participants with accelerated biological aging at baseline experienced greater benefits from the multivitamin, suggesting that this intervention may be particularly effective for individuals with higher biological age, potentially providing crucial insights for long-term health outcomes.
- Strategic Implications: This research offers new evidence for the potential role of multivitamins in healthy aging, highlighting Centrum Silver as a safe, low-cost intervention that may play a significant role in promoting health among older adults.
See More
Haleon plc Reports Profit Growth for Fiscal 2025 Despite Revenue Decline
- Significant Profit Growth: Haleon plc reported a 12.7% increase in fiscal 2025 profit before tax, reaching £2.15 billion, up from £1.91 billion last year, demonstrating strong profitability despite a revenue decline.
- Earnings Per Share Increase: The company's earnings per share rose by 17.8%, from 15.7 pence to 18.5 pence, reflecting successful cost control and operational efficiency, which enhances shareholder return expectations.
- Share Buyback Plan: Haleon announced a £500 million allocation for share buybacks in 2026, a move aimed not only at boosting earnings per share but also reflecting confidence in future cash flows, thereby enhancing market recognition of its long-term value.
- Future Growth Outlook: The company expects organic revenue growth of 3% to 5% for fiscal 2026, alongside high single-digit adjusted operating profit growth, indicating Haleon's strategic commitment to enhancing profitability and market competitiveness.
See More
